Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet-fed mice

Journal of Nutritional Biochemistry

Volumn 22, Issue 11, 2011, Pages 1064-1073

  Wang, Zhong Q ^a   Zhang, Xian H ^a   Yu, Yongmei ^a   Poulev, Alexander ^a,b   Ribnicky, David ^a,b   Floyd, Z Elizabeth ^a   Cefalu, William T ^a,b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Acyl carnitine; Bitter melon extract; High fat diet; IRS 1; PI 3Kinase

Indexed keywords

CARNITINE; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LEPTIN; LIPID; MOMORDICA CHARANTIA EXTRACT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE METABOLISM; HORMONE BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; MYOTUBE; NONHUMAN; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANIMALS; CARNITINE; CELLS, CULTURED; DIET, HIGH-FAT; GLUCOSE; INSULIN; MALE; MICE; MOMORDICA CHARANTIA; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; PLANT EXTRACTS; SIGNAL TRANSDUCTION;

CUCUMIS; MUS;

EID: 80053362207     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.09.004     Document Type: Article

References (40)

1. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
2. Reaven G.M. Role of insulin resistance in human disease. Diabetes 1998, 37:1595-1607.
3. Hill J.O., Wyatt H.R., Reed G.W., Peters J.C. Obesity and the environment: where do we go from here?. Science 2003, 299:853-855.
4. Basch E., Gabardi S., Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health-Syst Pharm 2003, 60:356-359.
5. McCarty M.F. Does bitter melon contain an activator of AMP-activated kinase?. Med Hypotheses 2004, 63:340-343.
6. Krawinkel M.B., Keding G.B. Bitter gourd (Momordica charantia): a dietary approach to hyperglycemia. Nutr Rev 2006, 64(7 Pt 1):331-337.
7. Shih C.C., Lin C.H., Lin W.L., Wu J.B. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J Ethnopharmacol 2009, 123(1):82-90.
8. Chao C.Y., Huang C.J. Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. J Biomed Sci 2003, 10(6 Pt 2):782-791.
9. Cummings E., Hundal H.S., Wackerhage H., Hope M., Belle M., Adeghate E., et al. Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. Mol Cell Biochem 2004, 261(1-2):99-104.
10. Sridhar M.G., Vinayagamoorthi R., Arul Suyambunathan V., Bobby Z., Selvaraj N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Br J Nutr 2008, 99(4):806-812.
11. Nerurkar P.V., Lee Y.K., Motosue M., Adeli K., Nerukar V.R. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphonositide-3 kinase interactions. Br J Nutr 2008, 100:751-759.
12. Zaid H., Antonescu C.N., Randhawa V.K., Klip A. Insulin action on glucose transporters through molecular switches, tracks and tethers. Biochem J 2008, 413(2):201-215.
13. Bajaj M., Baig R., Suraamornkul S., Hardies L.J., Coletta D.K., Cline G.W., et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. Clin Endocrinol Metab 2010, [Epub ahead of print].
14. Chan L.L.Y., Chen Q., Go A.G.G., Lam E.K.Y., Li E.T.S. Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J Nutr 2005, 135:2517-2523.
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
16. Wang Z.Q., Zuberi A.R., Zhang X.H., Macgowan J., Qin J., Ye X., et al. Effects of dietary fibers on weight gain, carbohydrate metabolism, and gastric ghrelin gene expression in mice fed a high-fat diet. Metabolism 2007, 56:1635-1642.
17. Wang Z.Q., Zhang X.H., Russell J.C., Hulver M., Cefalu W.T. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo obese, insulin-resistant JCR:LA-cp rats. J Nutr 2006, 136:415-420.
18. Stewart L.K., Wang Z., Ribnicky D., Soileau J.L., Cefalu W.T., Gettys T.W. Failure of dietary quercetin to alter the temporal progression of insulin resistance among tissues of C57BL/6J mice during the development of diet-induced obesity. Diabetologia 2009, 52(3):514-523.
19. Hajduch E., Alessi D.R., Hemmings B.A., Hundal H.S. Constitutive activation of protein kinase Bα (PKBα) by membrane targeting promotes glucose and system A amino acid transport, protein synthesis and GSK3 inactivation in L6 muscle cells. Diabetes 1998, 47:1006-1013.
20. Scarpace P.J., Zhang Y. Leptin resistance: a predisposing factor for diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2009, 296:R493-R500.
21. Zimmet P., Hodge A., Nicolson M., Staten M., deCourten M., Moore J., et al. Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study. Br Med J 1996, 313:965-969.
22. Morrison C.D., Huypens P., Stewart L.K., Gettys T.W. Implications of crosstalk between leptin and insulin signaling during the development of diet induced obesity. Biochim Biophys Acta 2009, 1792(5):409-416.
23. Perez C., Fernandez-Galaz C., Fernandez-Agullo T., Arribas C., Andres A., Ros M., et al. Leptin impairs insulin signaling in rat adipocytes. Diabetes 2004, 53:347-353.
24. Kim Y.W., Kim J.Y., Park Y.H., Park S.Y., Won K.C., Choi K.H., et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 2006, 55:716-724.
25. Huang W., dedousis N., Bhatt B.A., O'Doherty R.M. Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity. J Biol Chem 2004, 279:21695-21700.
26. Zhou Q.L., Park J.G., Jiang Z.Y., Holik J.J., Mitra P., Semiz S., et al. Analysis of insulin signalling by RNAi-based gene silencing. Biochem Soc Trans 2004, 32:817-821.
27. Tan K., Kimber W.A., Luan J., Soos M.A., Semple R.K., Wareham N.J., et al. Analysis of genetic variation in Akt2/PKB-β in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes. Diabetes 2007, 56:714-719.
28. Scheid M.P., Marignani P.A., Woodgett J.R. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 2002, 22:6247-6260.
29. Jiang Z.Y., Zhou Q.L., Coleman K.A., Chouinard M., Boese Q., Czech M.P. Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing. Proc Natl Acad Sci U S A 2003, 100:7569-7574.
30. Holman G.D., Kasuga M. From receptor to transporter: insulin signaling to glucose transport. Diabetologia 1997, 40:991-1003.
31. Kelley D.E., He J., Menshikova E.V., et al. Dysfunction in mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002, 51:2944-2950.
32. Petersen K.F., Dufour S., Befroy D., et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004, 350:664-671.
33. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008, 118:829-838.
34. Kraegen E.W., Clark P.W., Jenkins A.B., Daley E.A., Chisholm D.J., Storlien L.H. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991, 40:1397-1403.
35. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
36. Adams S.H., Hoppel C.L., Lok K.H., Zhao L., Wong S.W., Minkler P.E., et al. Plasma acyl carnitine profiles suggest incomplete fatty acid β-oxidation and altered tricarboxylic cycle activity in type 2 diabetic African-American women. J Nutr 2009, 139(6):1073-1081.
37. Su X., Han X., Mancuso D.J., Abendschein D.R., Gross R.W. Accumulation of long-chain acyl carnitine and 3-hydroxy acyl carnitine molecular species in diabetic myocardium: identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. Biochemistry 2005, 44(13):5234-5245.
38. Noland R.C., Koves T.R., Seiler S.E., Lum H., Lust R.M., Ilkayeva O., et al. Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolism control. J Biol Chem 2009, 284:22840-22852.
39. Koves T.R., Ussher J.R., slentz D., Mosedale M., Ilkayeva O., Bain J.R., et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metabolism 2008, 7:45-56.
40. Ahmed I., Adeghate E., Cummings E., Sharma A.K., Singh J. Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol Cell Biochem 2004, 261(1-2):63-70.